Atossa Therapeutics, Inc.’s Post

🔬 A recent study performed a review and meta-analysis of previously gathered clinical trial data to compare 1st line chemotherapy for advanced pancreatic ductal adenocarcinoma with other treatment options for #PDAC. 👉 Learn more about the efficacy and toxicity of various treatment options: https://buff.ly/40XY1SR #PancreaticCancerAwareness

More #Heme Today reporting of new data for presentation at #ASH24: Mehmet Sevki Uyanik, MD, of MD Anderson Cancer Center and colleagues bring evidence of #tagraxofusp plus #decitabine combo efficacy in #myelodysplasticsyndromes and #chronicmyelomonocyticleukemia. #MDS, #CMML https://lnkd.in/g_z3Hdw9

🚨 In the News 🚨 We’re excited to see Imbed Biosciences featured for their groundbreaking achievement! On October 31st, the FDA approved Microlyte Ag/Lidocaine, the first-ever antimicrobial wound dressing that combines lidocaine with silver for antimicrobial control. This innovative dressing brings dual benefits: providing antimicrobial protection and local anesthetic effects, ideal for managing painful wounds. Read the full mention on this in the article below, as Imbed Biosciences continues to lead the way in advanced wound care. 📖 #InTheNews #HealthcareInnovation #WoundCare #FDAApproval #PainManagement #ImbedBiosciences #MedicalBreakthrough

Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/ghgqwGiq #ClinicalTrials #ChooseCalyx

🚀 Advancing personalized tissue therapies: VERIGRAFT P-TEV clinical trial update 🚀 We are excited to share progress from our ongoing Phase I/II clinical trial in Europe! Eleven of the planned fifteen patients have now been treated with our Personalized Tissue-Engineered Vein (P-TEV) product, and four of these patients have completed the twelve-month follow-up period. Our trial aims to evaluate P-TEV’s potential to cure chronic venous insufficiency, a condition caused by faulty valves that fail to prevent venous blood backflow. Primary endpoints focus on safety, assessing risks such as infection, mechanical failure, and thrombosis. Secondary endpoints will measure treatment efficacy. “So far, the results are exceeding expectations, confirming safety and showing significant promise for our innovative approach,” said Petter Björquist, CEO of VERIGRAFT. “Our commitment to advancing regenerative medicine and providing personalized treatments that enhance recovery and improve quality of life is yielding encouraging outcomes." 🔗 Click the link in the comments section below to learn more about VERIGRAFT’s innovative tissue therapy technology 👇   #RegenerativeMedicine #ClinicalTrials #HealthInnovation #PersonalizedTherapies #PrecisionMedicine #ChronicVenousInsufficiency #PTEV #Gothenburg #Sweden #VERIGRAFT SwedenBIO CCRM Nordic Business Region Göteborg AB ATMP Sweden SwedenBIO Business Sweden

Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/g-WkB65v #ClinicalTrials #ChooseCalyx

Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/gYCpMghh #ClinicalTrials #ChooseCalyx

High response rate of anti-PD1 in Kaposi's sarcoma. This should be the new standard of care. https://lnkd.in/greE33aG

Employee health benefits that actually benefit PEOPLE. Take a look at our insightful webinar discussing HealthEZ's Medical Infusion Program (MICO) and learn how we put the patient at the center of everything that we do while continuing to control and predict cost for employee benefits. #HealthEZ #MICO #MedicalInfusions #CostContainment

Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/grwp5v7C #ClinicalTrials #ChooseCalyx